| 健康食品としての位置付け(医療効果の断定は不可) | CBDオイルは日々のリラックスや休息時間をサポートする健康食品(食用油脂)であり、免疫力の向上や病気の治療・予防といった医薬品的な効能を持つものではありません。 |
|---|---|
| 食用油脂区分の「THC残留限度値(10ppm)」への適合必須 | 改正大麻取締法により、CBDオイル(油脂類)に含まれるΔ9-THCの残留限度値は「10ppm(0.001%)以下」と厳格に定められています。 |
| 購入前に必ず確認すべき3点 | ①改正法施行後の最新基準に適合した成分分析証明書(COA)がロットごとに公開されていること、②食品としての日本語ラベル表示があること、③正規販売店であることです。 |
Corrected on 2026-10-20:We have retracted the medicinal claims in the headings and body text stating 'boosting immunity with CBD oil' as well as the purchase recommendations for specific products from our 2020 publication. The original publication date is retained.
- There Is No Evidence That CBD Oil 'Boosts Immunity' or 'Prevents Disease'
- 2026 Precautions Regarding Past 'Broad-Spectrum' CBD Oils
- CBD, THC, and CBN Are Different Substances: Check the 2026 Regulations
- 4 Certificate of Analysis (COA) Checkpoints Before Purchase or Use
- Why "Safe Because It Is CBD" or "Side-Effect-Free Because It Is Natural" Cannot Be Assumed
There Is No Evidence That CBD Oil 'Boosts Immunity' or 'Prevents Disease'
No medical evidence has been confirmed that drinking commercially available CBD oil or mixing it into beverages such as coffee boosts immunity or prevents infectious diseases. Please do not use CBD oil for the purpose of maintaining health or preventing or treating diseases.
2026 Precautions Regarding Past 'Broad-Spectrum' CBD Oils
Among overseas broad-spectrum CBD oils distributed in 2020, some contained minor cannabinoids other than CBD (such as CBN) or came from lots manufactured before Japan's Δ9-THC residual limit (oil category: 10ppm) took effect on 2024-12-12.
If you still have old CBD oil on hand or are researching overseas products, do not judge or use them without a latest Certificate of Analysis (COA) matching the lot number to confirm compliance with the CBN designated-substance regulation effective 2026-6-1 and the 10ppm THC standard.
CBD, THC, and CBN Are Different Substances: Check the 2026 Regulations
CBD (cannabidiol), CBN (cannabinol), and Δ9-THC are distinct compounds treated differently under Japanese law. Product names or package labels such as "CBD Product" or "Hemp-Derived" alone cannot determine all contained ingredients or legal compliance.
CBN became a designated substance on 2026-6-1.The Ministry of Health, Labour and Welfare prohibits in principle the manufacture, import, sale, possession, and use of CBN-containing products. While procedural exceptions exist for medical and research uses, they do not permit general consumer purchase or use. Do not rely on older reviews or past articles claiming "legal" or "recommended." Source:Ministry of Health, Labour and Welfare: Designation of CBN and Procedures.
In addition, category-specific residual limits for Δ9-THC took effect on 2024-12-12, and any product exceeding the threshold is classified as a narcotic. These figures are product concentration standards, not intake guidelines.
| Product Category | Residual Limit for Δ9-THC |
|---|---|
| Oils and fats (liquid at room temperature) and powders | 10ppm |
| Aqueous solutions | 0.10ppm |
| All other products (confectionery, solids, VAPE liquids, etc.) | 1ppm |
Product appearance or naming alone does not determine whether an item falls under the oils/fats category. You must verify the actual product category against a lot-specific Certificate of Analysis (COA). Source:Ministry of Health, Labour and Welfare: Legal Amendments and Residual Limits.
4 Certificate of Analysis (COA) Checkpoints Before Purchase or Use
- Match Between Product Name and Batch / Lot Number:Whether the lot number printed on your actual container matches the lot number on the report rather than a generic sample certificate.
- Testing Laboratory and Analysis Date:Whether the name of the third-party laboratory, date of testing, and analytical method are clearly stated.
- Limit of Quantification (LOQ) and Limit of Detection (LOD) for Δ9-THC:Whether testing sensitivity is below Japan's category-specific residual limits (10ppm / 0.10ppm / 1ppm), rather than merely stating "ND (Not Detected)."
- Absence of Designated Substances (Such as CBN) and Undeclared Ingredients:Whether CBN, a designated substance since 2026-6-1, is confirmed absent.
Avoid using products without verifiable lot numbers or items from unverified sources such as social media or flea-market apps, as actual contents may differ from the label.
Why "Safe Because It Is CBD" or "Side-Effect-Free Because It Is Natural" Cannot Be Assumed
The U.S. FDA highlights risks associated with CBD including liver injury, interactions with concurrent medications, pronounced drowsiness, diarrhea, and appetite changes, while noting scientific unknowns regarding long-term use and differences across intake routes (inhalation, oral, topical). Source:FDA: Risks and Unknowns of CBD Products.
Research on specific prescription CBD formulations cannot be treated as proof that commercial CBD oils, gummies, or VAPE liquids improve insomnia, relieve stress, boost immunity, or aid smoking cessation. Discontinue use immediately and consult a medical professional if you feel unwell. Anyone with preexisting conditions or taking medication should consult a physician or pharmacist rather than self-medicating.